Table 3.

Association of relative risk of treatment initiation, time to first treatment and overall survival with the mRNA expression of 17 genes selected for validation in early stage CLL patients (n = 93)

Association of RR, TTFT and OS with mRNA expression
S No.	Parameter (cut off)		Treatment required		RR of treatment initiation			TTFT (in months)					OS (in months)
			Yes	No	RR	95% CI	p value	Time	Events	HR	95% CI	p value	Time	Events	HR	95% CI	p value
1	CRY1 (0.678)	<0.678	16	31	1.91	1.221-3.006	0.01	83	13				NR	7
		>0.678	30	16				19	28	3.53	1.789-6.987	<0.001	NR	11	2.22	0.857-5.754	0.1
2	MEIS1 (0.057)	<0.057	23	23	0.97	0.64-1.47	0.92	48	21				NR	9
		>0.057	23	24				47	22	1.04	0.564-1.925	0.9	NR	9	1.06	0.421-2.707	0.89
3	ID4 (3.891)	<3.891	20	25	1.21	0.80-1.85	0.47	51	18				NR	11
		>3.891	26	22				47	23	1.06	0.571-1.975	0.85	NR	7	1.85	0.654-5.245	0.25
4	TNRC18 (0.646)	<0.646	24	22	0.89	0.59-1.35	0.76	43	22				NR	11
		>0.646	22	25				48	19	0.86	0.465-1.596	0.63	NR	7	0.64	0.248-1.657	0.36
5	NFATC1 (0.536)	<0.536	23	23	0.97	0.64-1.47	0.92	48	20				NR	7
		>0.536	23	24				36	21	1.45	0.775-2.712	0.25	NR	11	0.95	0.364-2.503	0.93
6	CDK6 (0.247)	<0.247	22	23	1.02	0.67-1.54	0.92	48	21				NR	7
		>0.247	24	24				47	22	1.05	0.570-1.945	0.87	NR	11	1.75	0.677-4.542	0.26
7	VIPR1 (7.21)	<7.210	19	26	1.33	0.87-2.03	0.25	48	17				NR	10
		>7.210	27	21				36	24	1.6	0.857-2.997	0.14	NR	8	0.98	0.384-2.508	0.97
8	SPRY1 (0.08)	<0.080	24	25	0.91	0.60-1.38	0.84	51	16				NR	11
		>0.080	22	24				29	25	1.77	0.949-3.335	0.07	NR	7	2.13	0.797-5.714	0.13
9	PAX9 (0.688)	<0.688	16	30	1.87	1.19-2.93	0.001	83	13				NR	5
		>0.688	30	16				19	28	3.14	1.589-6.205	<0.001	NR	13	3.29	1.172-9.272	0.02
10	PMEPA1 (0.01)	<0.010	19	27	1.42	0.93-2.16	0.14	51	17				NR	5
		>0.010	27	19				43	24	1.34	0.723-2.518	0.34	NR	13	1.97	0.698-5.565	0.2
11	TBX2 (0.085)	<0.085	24	21	0.87	0.583-1.322	0.68	48	21				NR	8
		>0.085	22	25				47	22	0.96	0.523-1.792	0.92	NR	10	1.44	0.567-3.655	0.44
12	TSHZ3 (1.073)	<1.073	25	21	0.84	0.556-1.268	0.52	47	20				NR	8
		>1.073	21	25				48	21	0.94	0.510-1.740	0.85	NR	10	1.38	0.546-3.511	0.49
13	BIK (0.438)	<0.438	19	26	1.33	0.87-2.04	0.25	43	16				NR	9
		>0.438	26	20				47	24	1.23	0.652-2.330	0.52	NR	9	0.8	0.319-2.052	0.66
14	SPRY2 (5.464)	<5.464	22	23	1.02	0.67-1.55	0.92	48	19				NR	10
		>5.464	23	23				48	21	0.86	0.459-1.614	0.64	NR	8	0.6	0.237-1.537	0.29
15	AXIN2 (5.979)	<5.979	23	22	0.93	0.61-1.41	0.92	29	21				NR	8
		>5.979	22	24				59	19	0.73	0.393-1.375	0.34	NR	10	1.06	0.418-2.695	0.9
16	SOX7 (0.162)	<0.162	20	25	1.22	0.80-1.86	0.46	48	18				NR	10
		>0.162	25	21				47	22	1.15	0.620-2.163	0.64	NR	8	0.68	0.270-1.744	0.43
17	RIC8B (1.741)	<1.741	19	24	1.22	0.80-1.87	0.46	48	17				NR	10
		>1.741	26	22				43	23	1.08	0.577-2.028	0.81	NR	8	0.57	0.226-1.463	0.25

Abbreviations used: RR relative risk, TTFT time to first treatment, OS overall survival, NR not reached, HR hazard ratio

The statistically significant p values are shown in italics